Hoechst-Roussel intermittent claudication consumer ad
The firm began running its revised institutional television ad campaign for intermittent claudication the week of Dec. 23. The ad is scheduled to run two-three weeks. A similar ad appears in print media, including the New York Times, USA Today, and TV Guide. The television ad is a revision of a previous Hoechst ad to which FDA objected. FDA asserted that the earlier ad's emphasis on availability of a drug (the unspecified Trental) constituted an advertisement for a specific Rx drug ("The Pink Sheet" Oct. 21, T&G-5).
You may also be interested in...
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.